GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE294nnn/GSE294635/primaryOK200TranscriptomicsHomo sapiensExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294635GEOGSEfalseRNA profiling of wild-type Osteosarcoma (U2OS) cells and its KO derivative (PERK KO) upon Palbociclib treatment for 4 daysDysregulation of cyclin-dependent kinase 4/6 (CDK4/6) occurs in various cancers. Three CDK4/6 inhibitors are approved for clinical use including Palbociclib (PD). CDK4/6 inhibitors trigger early G1 cell cycle arrest in cells, leading to cellular quiescence while long term inhibition enforces transition to senescence. PERK is a shared Kinase between the Unfolded Protein Response (UPR) and the Integrated Stress Response (ISR). We report that PERK inhibition accelerate Palbociclib induce senescence.2026/04/30GSE294635GSM8913061GSM8913066GSM8913067GSM8913068GSM8913069GSM8913062GSM8913063GSM8913064GSM891306534284294635Homo sapiens